À¯¹æ ¿µ»ó Áø´Ü ½ÃÀåÀº 2025³â 50¾ï 7,500¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 73¾ï 9,400¸¸ ´Þ·¯·Î ¼ºÀåÇϸç, CAGRÀº 7.82%·Î ¿¹ÃøµË´Ï´Ù.
À¯¹æ¾Ï ¹ßº´·ü ¹× ÀÎÁöµµ Áõ°¡
¼¼°èº¸°Ç±â±¸(WHO)°¡ ÁöÀûÇÑ ¹Ù¿Í °°ÀÌ À¯¹æ¾ÏÀº ¿©ÀüÈ÷ Àü ¼¼°è¿¡¼ ¿©¼ºÀÌ °¡Àå ¸¹ÀÌ °É¸®´Â ¾Ï Áß ÇϳªÀ̸ç, ¼±Áø±¹°ú °³¹ßµµ»ó±¹À» ¸··ÐÇϰí Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. »ýÁ¸À²ÀÌ ³·Àº ÁÖ¿ä ¿øÀÎÀº Á¶±â¹ß°ß ÇÁ·Î±×·¥ÀÌ ¹ÌÈíÇϰí Á¤±â°ËÁø¿¡ ´ëÇÑ ÀνÄÀÌ ³·¾Æ ¸»±â Áø´ÜÀ¸·Î À̾îÁö´Â °æ¿ì°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù. À¯¹æ¾Ï ¹ßº´·üÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â ¹ß°ßÀ» ÅëÇØ À§ÇèÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ´Â Àû±â °ËÁøÀÇ Á߿伺¿¡ ´ëÇÑ ¿©¼ºµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È·Î ÀÎÇØ ÷´Ü À¯¹æ ¿µ»ó Áø´Ü Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Áø´Ü Á¤È®µµ¿Í ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ´Â ±â¼úÀ» ¿ì¼±½ÃÇÔ¿¡ µû¶ó ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
÷´Ü ¿µ»ó Áø´Ü ±â¼ú µµÀÔ
½ÃÀåÀº Áø´Ü È¿À²À» Çâ»ó½ÃŰ´Â Çõ½ÅÀûÀÎ À¯¹æ ¿µ»ó Áø´Ü¹ýÀÇ Ã¤ÅÃÀ¸·Î ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ºÐÀÚ À¯¹æ ¿µ»ó¹ý(MBI), Á¶¿µ À¯¹æÃÔ¿µ¼ú(CEM), ¾çÀüÀÚ ¹æÃâ À¯¹æÃÔ¿µ¼ú(PEM), Àü±â ÀÓÇÇ´ø½º °Ë»ç(EIT), ±¤ÇÐ ¿µ»ó °Ë»ç µîÀÇ ±â¼úÀÌ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÇÙÀÇÇÐÀûÀÎ Á¢±Ù¹ýÀÎ MBI´Â ÈÇÐÀû ÃßÀûÀÚ¸¦ ÁÖÀÔÇϰí Àü¿ë Ä«¸Þ¶ó¸¦ »ç¿ëÇÏ¿© À¯¹æÀÇ ÀÌ»óÀ» Æò°¡ÇÏ´Â °ÍÀ¸·Î, ƯÈ÷ À¯¹æ¹Ðµµ°¡ ³ôÀº ¿©¼ºÀ̳ª À¯¹æÃÔ¿µ¼ú¿¡ ÀÌ»óÀÌ ÀÖ´Â ¿©¼º¿¡°Ô ÀûÇÕÇϸç, CEMÀº ¿ä¿Àµå ±â¹Ý Á¶¿µÁ¦¸¦ »ç¿ëÇÏ¿© ºñÁ¤»óÀûÀÎ À¯¹æÁ¶Á÷À» °Á¶ÇÏ´Â °Ë»ç·Î, MRI¿¡ ºñÇØ ºñ¿ë ´ëºñ È¿°úÀûÀ̸ç PET °Ë»ç¿Í À¯»çÇÑ PEMÀº ¹æ»ç¼º ´çÀ» »ç¿ëÇÏ¿© ÀÛÀº ¾Ï¼¼Æ÷±ºÀ» °ËÃâÇϰí, EIT´Â ¾Ï¼¼Æ÷¿Í Á¤»ó¼¼Æ÷ÀÇ Àü±âÀüµµµµ Â÷À̸¦ ÀÌ¿ëÇϸç, ±¤ À̹Ì¡Àº ºûÀÇ Åõ°úÀ²À» ºÐ¼®ÇÏ¿© ¾ÏÀÇ ¼ºÀåÀ» ¸ð´ÏÅ͸µÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹æ¹ýµéÀº MBI¿Í PEMÀÇ ¹æ»ç¼± ÇÇÆø µîÀÇ ¹®Á¦Á¡¿¡µµ ºÒ±¸ÇÏ°í º¸´Ù Á¤¹ÐÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ½ÃÀå ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
±â¼ú ¹ßÀü
À¯¹æ ¿µ»ó Áø´Ü ±â¼úÀÇ ²÷ÀÓ¾ø´Â Çõ½ÅÀº ÁÖ¿ä ÃËÁøÁ¦ÀÔ´Ï´Ù. ¾Ï¼¼Æ÷ÀÇ È®»êÀ» °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â ±â´ÉÀÌ Çâ»óµÈ ÷´Ü ½Ã½ºÅÛÀÌ °³¹ßµÇ¾î Áø´ÜÀÇ Á¤È®¼º°ú ¿öÅ©Ç÷οìÀÇ È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. °¢ Á¦Á¶¾÷üµéÀÌ ´Ù¾çÇÑ °í¼º´É À̹Ì¡ ¼Ö·ç¼ÇÀ» µµÀÔÇϰí ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ ÀÇ·á ÇöÀå¿¡¼ÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º¸´Ù ºü¸£°í Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇϴ ÷´Ü Àåºñ¿¡ ´ëÇÑ °ü½ÉÀº À¯¹æ¾ÏÀ» Á¶±â¿¡ È¿°úÀûÀ¸·Î ¹ß°ßÇÏ·Á´Â ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ³ë·ÂÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
±â¼úÀÇ ¹ßÀü¿¡µµ ºÒ±¸Çϰí MBI³ª PEM°ú °°Àº ƯÁ¤ ¿µ»ó Áø´Ü ±â¼úÀº ¹æ»ç¼± ³ëÃâ·Î ÀÎÇØ ÀÏ»óÀûÀÎ °ËÁø¿¡¼ »ç¿ëÀÌ Á¦ÇѵǾî ÀÖÀ¸¸ç, EIT³ª ±¤ÇÐ ¿µ»ó Áø´Ü°ú °°Àº »õ·Î¿î ¹æ¹ýÀº Ãß°¡ÀûÀÎ ÀÓ»óÀû °ËÁõ°ú ÀÎÇÁ¶ó ÅõÀÚ°¡ ÇÊ¿äÇÏ¿© º¸±Þ¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦µéÀº Áø´ÜÀÇ À¯È¿¼º°ú ȯÀÚÀÇ ¾ÈÀü¼º ¹× Á¢±Ù¼º »çÀÌÀÇ ±ÕÇüÀ» ¸ÂÃß±â À§ÇÑ Áö¼ÓÀûÀÎ Á¶»çÀÇ Çʿ伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù.
Áö¿ªº° Àü¸Á
ºÏ¹Ì´Â ³ôÀº À¯¹æ¾Ï ¹ßº´·ü°ú »ç¸Á·ü Áõ°¡·Î ÀÎÇØ ÷´Ü ¿µ»ó Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ¿Í ÀÎ½Ä Á¦°í Ä·ÆäÀÎÀÌ È°¹ßÈ÷ ÁøÇàµÇ¸é¼ ¿¹Ãø ±â°£ Áß ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áø´Ü ½Ã¼³ ¹× ÀÇ·á ÀÎÇÁ¶ó¸¦ °ÈÇϱâ À§ÇÑ ³ë·Â¿¡ ÈûÀÔ¾î ½ÃÀå Á¡À¯À²À» È®´ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ªÀû µ¿ÇâÀº ÇコÄÉ¾î ¿ì¼±¼øÀ§¿Í ÅõÀÚÀÇ Â÷À̸¦ ¹Ý¿µÇÏ¿© ½ÃÀåÀÇ ¼ºÀå ±Ëµµ¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù.
°á·Ð
À¯¹æ¾Ï ȯÀÚ Áõ°¡, Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Çõ½ÅÀûÀÎ ¿µ»ó ±â¼ú¿¡ ÈûÀÔ¾î À¯¹æ ¿µ»ó Áø´Ü ½ÃÀåÀº °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â ³ôÀº Áúº´ À¯º´·ü°ú ÅõÀÚ ±Ô¸ð¿¡¼ ¼±µÎ¸¦ ´Þ¸®°í ÀÖÀ¸¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áø´Ü ÀÎÇÁ¶ó °³¼±À» ÅëÇØ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹æ»ç¼± À§Çè ¹× µµÀÔ À庮°ú °°Àº °úÁ¦¿¡µµ ºÒ±¸Çϰí MBI, CEM, PEM, EIT, ±¤ÇÐ À̹Ì¡ µîÀÇ ¹ßÀüÀ¸·Î ½ÃÀå ±âȸ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¾÷°è Àü¹®°¡µéÀº ½ÃÀåÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ ÀÖÀ¸¸ç, ±â¼ú Çõ½Å°ú Áö¿ª ¿ªÇÐÀÇ Áß¿äÇÑ ¿ªÇÒ¿¡ ÁÖ¸ñÇØ¾ß ÇÕ´Ï´Ù.
¾î¶² ¿ëµµ·Î »ç¿ëµÇ´Â°¡?
»ê¾÷ ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÃâ Àü·«, Áö¿ªÀû È®Àå, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¿µÇâ, ½ÅÁ¦Ç° °³¹ß, °æÀïÀÇ ¿µÇâ
The Global Breast Imaging Market is expected to grow from USD 5.075 billion in 2025 to USD 7.394 billion in 2030, at a CAGR of 7.82%.
Increasing Breast Cancer Incidence and Awareness
Breast cancer remains one of the most prevalent cancers affecting women globally, as noted by the World Health Organization, with significant impact in both developed and developing nations. Low survival rates are primarily due to inadequate early detection programs and limited awareness of routine screenings, leading to late-stage diagnoses. The growing incidence of breast cancer is driving heightened awareness among women about the importance of timely checkups, which significantly reduce risks through early detection. This shift is increasing demand for advanced breast imaging equipment, fueling market expansion as healthcare providers prioritize technologies that enhance diagnostic accuracy and patient outcomes.
Adoption of Advanced Imaging Techniques
The market is benefiting from the adoption of innovative breast imaging methods that improve diagnostic efficiency. Techniques such as molecular breast imaging (MBI), contrast-enhanced mammography (CEM), positron emission mammography (PEM), electrical impedance testing (EIT), and optical imaging tests are gaining traction. MBI, a nuclear medicine approach, involves injecting a chemical tracer and using a specialized camera to evaluate breast abnormalities, particularly for women with dense breasts or abnormal mammograms. CEM uses iodine-based contrast dye to highlight abnormal breast tissue, offering a cost-effective alternative to MRI. PEM, akin to PET scans, employs radioactive sugar to detect small cancer cell clusters. EIT leverages differences in electrical conductivity between cancerous and normal cells, while optical imaging analyzes light transmission to monitor cancer growth. These methods, despite challenges like radiation exposure in MBI and PEM, are driving the development of enhanced imaging equipment, contributing to market growth by enabling more precise diagnostics.
Technological Advancements
Continuous innovation in breast imaging technologies is a key growth driver. Advanced systems with improved capabilities for detecting and monitoring cancer cell spread are being developed, enhancing diagnostic precision and workflow efficiency. These advancements are expected to increase adoption across healthcare settings, as manufacturers introduce diverse, high-performance imaging solutions. The focus on sophisticated equipment that delivers faster, more accurate results is anticipated to propel market growth over the forecast period, as providers seek to meet rising demand for early and effective breast cancer detection.
Market Challenges
Despite technological progress, certain imaging techniques, such as MBI and PEM, involve radiation exposure, limiting their use in routine screening. Emerging methods like EIT and optical imaging require further clinical validation and infrastructure investment, posing barriers to widespread adoption. These challenges highlight the need for ongoing research to balance diagnostic efficacy with patient safety and accessibility.
Regional Outlook
North America is expected to maintain a dominant market share through the forecast period, driven by the high prevalence of breast cancer and increasing mortality rates, which are prompting greater investment in advanced imaging solutions and awareness campaigns. The Asia Pacific region is poised to expand its market share, supported by initiatives to enhance diagnostic facilities and healthcare infrastructure. These regional trends reflect varying healthcare priorities and investments, shaping the market's growth trajectory.
Conclusion
The breast imaging market is on a strong growth path, driven by rising breast cancer cases, growing awareness of early detection, and innovative imaging technologies. North America leads due to high disease prevalence and investment, while Asia Pacific is set to grow through improved diagnostic infrastructure. Despite challenges like radiation risks and adoption barriers, advancements in MBI, CEM, PEM, EIT, and optical imaging are expanding market opportunities. Industry experts should note the critical role of technological innovation and regional dynamics in shaping the market's future.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Segmentation: